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An investigation into the role of CD45 isoforms in T
cell antigen receptor signal transduction was carried
out by transfecting CD45-negative CD4CD8 HPB-ALL
T cells with the CD45R0, CD45RBC, and CD45RABC iso-
forms. Fluorescence resonance energy transfer analysis
showed that the CD45R0 isoform, but not the CD45RBC
or CD45RABC isoforms, was found as homodimers and
also preferentially associated with CD4 and CD8 at the
cell-surface. A comparison was therefore made of T cell
antigen receptor signaling between sub-clones express-
ing either CD45R0 or CD45RBC. Under basal conditions
CD4-associated p56lck tyrosine kinase activity and cellu-
lar protein tyrosine phosphorylation levels were higher
in the CD45R0 than in the CD45RBC sub-clones. Upon
CD3-CD4 ligation, TCR- phosphorylation, ZAP-70 re-
cruitment to the p21/p23 TCR- phosphoisomers, ZAP-70
phosphorylation, as well as p56lck, c-Cbl and Slp-76 phos-
phorylation, were all markedly increased in CD45R0
compared with CD45RBC cells. T cell antigen receptor
(TCR) stimulation alone also promoted c-Cbl phospho-
rylation in CD45R0 but not in CD45RBC cells. Our
results are consistent with a model in which association
of CD45R0 with CD4 generates a more active pool of
CD4-associated p56lck kinase molecules. Upon CD3-CD4
co-ligation, the active p56lck increases the intensity of T
cell antigen receptor signal transduction coupling by
promoting TCR- chain phosphorylation and ZAP-70
recruitment.
The CD45 tyrosine phosphatase regulates the threshold of T
cell antigen receptor (TCR)1 signaling by modulating the ac-
tions of the p56lck and p59fyn tyrosine kinases (1–4). The p56lck
kinase associates with the CD4 and CD8 co-receptors and ini-
tiates TCR signaling cascades by phosphorylation of immuno-
receptor tyrosine-based activation motifs located in the TCR-
and CD3- chains (5, 6). In CD45/ mice T cell development is
severely affected (7, 8), and elevated TCR signaling thresholds
are marked by dysfunctional p56lck, together with defective
TCR- chain phosphorylation and ZAP-70 recruitment (9).
CD45 exerts a positive effect on p56lck actions by de-phospho-
rylating the inhibitory C-terminal pTyr-505 (10–13), but can
also negatively regulate the kinase by dephosphorylating the
pTyr-394 autophosphorylation site (14, 15). The actions of
CD45 on p56lck in CD4 T cells are directed selectively at the
CD4-associated pool of the kinase (16). The dominant effect of
CD45 in the T-lineage appears to be at pTyr-505, since T cell
development in CD45/ mice can be largely restored by back-
crossing to mice expressing the mutant lckY505F-active trans-
gene (17, 18).
Alternative splicing generates up to eight different CD45
isoforms (19, 20) of which five are expressed at significant
levels in T cells (21). All T cells express more than one CD45
isoform, and differential isoform expression is tightly con-
trolled during thymic development and the activation of ma-
ture T cells (reviewed in Ref.1). However, the molecular conse-
quences of differential CD45 isoform expression for TCR
signaling, if any, are not yet well understood. Reconstitution of
a murine CD45 cell line with CD45 isoforms suggested that
the CD45R0 isoform (lacking the A, B, and C exon-encoded
segments of the ectodomain) promoted greater interleukin-2
secretion upon engagement of the TCR with the cognate major
histocompatibility complex-peptide as compared with other iso-
forms (22). Co-capping experiments in these cells revealed pref-
erential CD4-CD45R0 association (23). However, more detailed
capping and co-immunoprecipitation studies indicated a basal
association of CD45R0 with the TCR independent of CD4 ex-
pression and suggested that co-capping of CD4 with CD45R0
was mediated by this prior CD45R0-TCR association (24). Nev-
ertheless CD4-CD45 association has also been described in
primary CD4 T cells (25, 26). In Jurkat T cells transfected
with different isoforms, the CD45R0 isoform was found to
promote greater interleukin-2 secretion in comparison with
CD45RABC cells, but conversely TCR-stimulated protein ty-
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rosine phosphorylation was generally higher in CD45RABC
than in CD45R0 cells (27).
Homodimeric forms of CD45 revealed by chemical cross-
linking (28), or by the introduction of cysteine residues into the
extracellular domain of CD45 adjacent to the transmembrane
domain to stabilize homodimers by the formation of disulfide
bonds (29), have also been described. It has been suggested that
homodimerization of CD45 may lead to inhibition of its tyrosine
phosphatase (PTPase) activity (29, 30). Mutation of the puta-
tive inhibitory wedge domain in an epidermal growth factor-
CD45 chimeric receptor to prevent epidermal growth factor-
induced homodimerization relieved the inhibitory effects of
epidermal growth factor on TCR-mediated signaling (30). In-
troduction of the same point mutation in a mouse line resulted
in autoimmunity, consistent with the prevention of inhibition
of CD45 PTPase activity (29). It has been hypothesized that the
CD45R0 isoform might homodimerize substantially, perhaps
due to engagement by a putative exogenous ligand, so prefer-
entially being subject to negative regulation by the inhibitory
wedge (29). This model suggests that CD45R0 homodimers
should exert a negative effect on TCR signaling.
In the present work we have used the well characterized
CD45 HPB-ALL T cell line (31). In the absence of CD45, TCR
signaling in this CD4CD8 line is largely ablated but can be
restored by transfection of CD45 cDNA (31, 32). We have trans-
fected this line with three different CD45 isoforms and used
fluorescence energy resonance transfer (FRET), a technique
that obviates the need for co-capping or detergent lysis, to show
that CD45R0, but not the CD45RBC or CD45RABC isoforms,
exists as homodimers and also associates preferentially with
CD4 and CD8. Investigation of TCR signaling shows that the
higher activity of CD4-associated p56lck in CD45R0 cells cor-
relates with elevated basal protein phosphorylation and with
enhanced TCR signal transduction intensity.
EXPERIMENTAL PROCEDURES
Materials—The following mAbs were used for routine FACS analysis
and cell-sorting: UCHT1 (CD3), pan-CD45-FITC (clone F10–89-4),
UCHL1-PE (CD45R0), CD45RA-PE (clone F8–11-13), and CD45RC
(clone YTH80.103) (Serotec, Oxford, UK); CD4 (clone 13B8.2) from
Beckman Coulter (Bucks, UK); CD8 (clone UCT4) from Sigma; and
CD45RB-FITC (clone PD7/26) from DAKO (Cambs, UK). The following
mAbs were used for FRET analysis: CD3 (MEM57, IgG2a), CD4
(MEM115, IgG2a), and CD8 (MEM31, IgG2a) from Prof. Vaclav Horejsi
(Prague, Czech Republic); pan-CD45 (CD45.2, IgG1) from Prof. S.
Meuer (Heidelberg, Germany). The following mAbs were used for stim-
ulation experiments: CD3-biotin (clone MCA463B) and CD4-biotin
(clone MCA 1267B) (Serotec). Antibodies were cross-linked with
streptavidin (Sigma). Immunoprecipitating antibodies used were Fb2
phosphotyrosine mAb (from Prof. D. Cantrell, Imperial Cancer Re-
search Fund, London, UK), CD4 (QS4120) mAb and goat anti- N39
(CT-11) antiserum (from Prof. C. Terhorst, Boston, MA). Western blot-
ting antibodies were used against phosphotyrosine (4G10), Vav and
c-Cbl (Upstate Biotechnology), ERK1 (Santa Cruz, Santa Cruz, CA),
ERK2 and Syk (Transduction Laboratories), p59fyn (from Dr. R.
Abraham, Mayo Clinic, Rochester, MN), phospho-p44/42 MAP kinase
(New England Biolabs, Beverly, MA), LAT and p56lck (from Dr L.
Samelson, NIH, Bethesda, MD), SLP-76 (from Dr G. Koretzky, Univer-
sity of Pennsylvania Medical School), ZAP-70 (from Glaxo-Smith-
Kline), and TCR- chain (Zymed Laboratories Inc.). Horseradish perox-
idase-conjugated secondary antibodies were from DAKO (Ely, UK). The
vector expressing the Grb-2 GST-fusion protein was from Prof. D.
Cantrell. Constructs containing cDNA encoding human CD45R0,
CD45RBC, and CD45RABC isoforms in a retroviral vector pZ-
ipNeoSV(X) (33) were from Prof. M. Streuli (Harvard University, Bos-
ton, MA).
Cells—The CD45 HPB-ALL sub-clone has been previously de-
scribed (31). Cells were cultured in RPMI 1640 with added penicillin,
streptomycin, and 5% fetal calf serum. Stable transfectants of CD45
isoforms were sorted by flow cytometry to generate sub-clones with
comparable CD3, CD4, CD8, and CD45 expression. Cells were routinely
analyzed using CD45 isoform-specific mAbs to confirm the specificity of
isoform expression. The CD45R0SD and CD45R0LG sub-clones were
transfected with human Lck cDNA (from Dr. C. Butcher, The Yaman-
ouchi Institute, Oxford, UK) sub-cloned into pcDNA3.1/Zeo (Invitrogen,
Leek, Netherlands). For stimulation experiments, HPB-ALL cells were
resuspended in RPMI without fetal calf serum and allowed to rest for 20
min at 37 °C before adding biotin-CD3 and biotin-CD4 mAbs (at 1
g/ml) or biotin-CD3 alone, for 2 min prior to addition of streptavidin (to
20 g/ml) for the times shown.
Northern Blot Analysis—Northern blot analysis was carried out us-
ing 10 g of total RNA from each HPB-ALL sub-clone, and blots were
probed using a 32P-labeled 1.5-kb EcoRI-NotI DNA fragment from
pCR2.1/hLck. Membranes were stripped and reprobed with a 32P-la-
beled gylceraldehyde 3-phosphate dehydrogenase (GAPDH) probe as a
loading control.
Fluorescence Resonance Energy Transfer—F(ab) fragments were
prepared by digestion of purified IgG with activated papain at 37 °C for
11 min. The enzyme activity was terminated by addition of iodoacet-
amide. The reaction mixture was passed through a Sephadex G-100 fine
column and the collected F(ab) fractions were further separated from
intact IgG on a protein A-Sepharose column. Purified mAbs and F(ab)
fragments were conjugated with 6-(fluorescein-5-carboxamido)-hex-
anoic acid succinimidyl ester and 6-(tetramethylrhodamine-5-carbox-
amido)-hexanoic acid succinimidyl ester (Molecular Probes, Eugene,
OR) or with sulfoindo-cyanin succinimidyl bifunctional ester derivative
of Cy-3 and Cy-5 (Amersham Biosciences, Inc.) as described (34). The
dye:protein ratios were separately determined for each labeled aliquot
by spectrophotometric measurements and in the case of F(ab) frag-
ments were 1. The fluorescently tagged antibodies and F(ab) frag-
ments retained their binding capacity according to competition assays
with identical but unlabeled antibodies. Shortly before use, conjugated
F(ab) fragments were centrifuged at 100,000  g for 30 min to remove
any complexes that may have formed during storage. Separation of
F(ab) fragments from supernatants on a sizing column revealed single
peaks of the expected molecular weight.
For labeling of cell surface antigens, cells were washed twice in PBS
and resuspended in PBS with 0.1% bovine serum albumin. About 106
cells in 50 l of PBS were incubated with fluorescently tagged antibod-
ies or F(ab) fragments at saturating concentration for 30 min on ice in
the dark. The applied antibody concentration (50–100 g/ml) saturated
all available binding sites. The excess mAb or F(ab) fragment was
removed by washing the cells twice in PBS. Cells were either used
immediately for measurements or were fixed in 1% formaldehyde. Data
obtained with fixed cells did not differ significantly from those of un-
fixed, viable cells.
FRET measurements were carried out using a Becton Dickinson
FACScan flow cytometer to determine FRET efficiency between fluo-
rescein- and rhodamine-conjugated mAb. In brief, the donor fluores-
cence was excited with the 488 nm line of an argon ion laser, and
fluorescence emission of the donor was detected at 530  30 nm. Donor
fluorescence of the double-labeled samples was compared with that of
samples where the acceptor antibody was replaced by non-labeled an-
tibody to compensate for any competition between the donor and accep-
tor antibodies. FRET efficiency was calculated from the fractional de-
crease of the donor fluorescence in the presence of the acceptor.
Flow cytometric FRET measurements to determine homoassociation
of Cy-3- and Cy-5-labeled antigens were carried out using a Becton
Dickinson FACScalibur flow cytometer. Four fluorescence intensities
were measured. Three were excited at 488 nm and detected at 530 30
nm, 585  42 nm, and above 670 nm, whereas the fourth was excited at
635 nm and detected at 661  16 nm. Correction factors for the spectral
overlap between the different fluorescence channels were obtained from
data measured on unlabeled and single-labeled cells. Forward and side
angle light scattering were used to gate out debris and dead cells. We
calculated the energy transfer efficiency on a cell-by-cell basis from the
four fluorescence intensities on 10,000 cells using list mode data. Cor-
rection of autofluorescence was carried out on a cell-by-cell basis to
eliminate the effect of low signal to noise ratios.
Calculated values for the energy transfer efficiency were expressed
as the ratio of the number of excited donor molecules tunneling their
excitation energy to the acceptor, to the number of all excited molecules.
The transfer efficiency is related to the inverse sixth power of the
separation between the donor and the acceptor when the orientation
factor of the donor’s excitation and the acceptor’s emission dipoles can
be considered as a statistical average of random orientation (35). The
calculated energy transfer efficiency has an extremely high sensitivity
to changes in distance within the range 1–10 nm. Larger energy trans-
fer efficiencies may reflect closer physical association of the donor- and
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acceptor-labeled antibodies or a larger density of acceptor-labeled an-
tibodies in the vicinity of donor-labeled antibodies (36, 37).
Immunoprecipitation and Immunoblotting—Stimulated cells were
lysed for 10 min at 4 °C in 1% Nonidet P-40, 20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EGTA, 1 mM sodium orthovanadate, and protease
inhibitors (protease inhibitor mixture tablets, Roche Molecular Bio-
chemicals, Sussex, UK). Nuclei and cellular debris were removed by
centrifugation for 10 min at 10,000 rpm at 4 °C. For analysis of whole
cell lysates by immunoblotting, samples (equivalent to 106 cells) were
added to Laemmli’s buffer and boiled for 5 min. For TCR- immunopre-
cipitation the lysates were pre-cleared by rotating at 4 °C for 30–60 min
with 40 l of 50% packed protein G-Sepharose beads (Pharmacia Bio-
tech). Pre-cleared lysates were incubated at 4 °C for 60 min or overnight
with immunoprecipitating antibody. Immune complexes were recovered
by incubation with 40 l of 50% packed protein G-Sepharose beads for
1 h at 4 °C. Pellets were washed three times with lysis buffer, re-
suspended in Laemmli’s buffer, and boiled for 5 min prior to separation
using 7.5–15% gradient gels. For CD4 immunoprecipitates, cells were
coated with CD4 mAb (QS4120) at 5 g/ml for 30 min on ice prior to
immunoprecipitation using protein G-Sepharose beads as above. For in
vitro kinase assay, immune complexes were washed once in kinase
buffer (50 mM Pipes, pH 7.4, 10 mM MnCl2, 10 mM MgCl2, 1 mM sodium
orthovanadate, and 1 mM AEBSF). The kinase reaction was initiated by
the addition of 30 l of kinase buffer containing 1 mM dithiothreitol, 5
M unlabeled ATP, and 1 Ci of [-32P]ATP (PerkinElmer Life Scienc-
es). Samples were incubated for 10 min at room temperature, and the
reaction stopped by the addition of 30 l of Laemmli’s buffer and boiling
for 5 min. Quantification of immunoblots and autoradiographs was
carried out using a LAS-1000 CCD camera and AIDA imaging software
(Fuji Photo Film Company).
RESULTS
A CD45 sub-clone of HPB-ALL T leukemia cells (31) was
used to generate stable transfectants expressing specific CD45
isoforms. Two CD45R0 sub-clones were obtained from the
same CD45 parental cell-line, generated in two different lab-
oratories (CD45R0SD and CD45R0LG). Two further sub-clones
were made expressing either the CD45RABC or CD45RBC
isoforms. Initial experiments (data not shown) revealed that
upon TCR stimulation or CD3-CD4 ligation, protein tyrosine
phosphorylation and other signals were greatly reduced in both
of the CD45R0 sub-clones in comparison with cells expressing
either CD45RABC or CD45RBC. This result was surprising in
light of previously published findings suggesting that CD45R0
may promote TCR signaling (22). However, as Fig. 1 illus-
trates, whereas the expression of the important signaling mol-
ecules Syk, ZAP-70, and p59fyn were found to be comparable
between the HPB-ALL sub-clones (Fig. 1a), both CD45R0
sub-clones expressed very low levels of p56lck, up to 20-fold
lower than the expression level in the CD45RBC sub-clone
(Fig. 1b, upper panel). Furthermore, p56lck was expressed
2-fold higher in the CD45RBC than in the CD45RABC sub-
clone. Northern analysis revealed that Lck mRNA levels
closely matched the protein expression differences (Fig. 1b,
lower panel). The parental CD45 sub-clone also had low p56lck
expression, although not as low as the two CD45R0 sub-
clones. Since the CD45R0 sub-clones were independently gen-
erated, we cannot exclude the possibility that differential CD45
isoform expression regulates Lck mRNA levels, but the low
p56lck expression in the CD45R0 sub-clones might also be
coincidental.
Since p56lck is critical as the kinase that promotes TCR-
phosphorylation, thereby initiating downstream signaling cas-
cades, the two CD45R0 sub-clones were stably transfected
with p56lck to generate a large number of clones expressing
varying p56lck levels. Sub-clones were picked to match the
CD45RBC and CD45RABC sub-clones for p56lck expression,
as well as for CD3, CD45, CD4, and CD8 expression (Fig. 2). We
then measured the differential association of CD45 isoforms
with CD4 and CD8 at the cell surface by FRET analysis. This
technique has the advantage that it detects associations by
FACS measurements using intact cells and avoids any require-
ment to expose the CD45 molecules to detergent. Measure-
ments were carried out using F(ab) fragments bound to fluoro-
phores rather than intact IgG molecules to avoid any cross-
FIG. 1. Expression of signaling molecules in HPB-ALL sub-
clones. a, immunoblotting of whole cell lysates for Syk, ZAP-70, and
p59fyn. b, immunoblotting of whole cell lysates for p56lck and Grb-2
protein (upper panel) and Northern blotting for p56lck and GAPDH
mRNA (lower panel). The values shown are the relative expression
levels of p56lck protein normalized for Grb-2 (upper panel) and of p56lck
mRNA normalized for GAPDH (lower panel).
FIG. 2. Antigen cell-surface expression in CD45R0 and
CD45RBC HPB-ALL sub-clones. CD45R0 (continuous line) or
CD45RBC (dotted line) HPB-ALL cells were stained for CD3, CD4,
CD8, and CD45 as shown and analyzed by FACS. The filled area in the
CD3 histogram shows the staining of isotype-matched control mAbs.
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linking of the molecules under investigation. Either fluorescein
or rhodamine were used in each experiment as fluorescence
donor or acceptor molecules, thereby generating two energy
transfer efficiency values for each antibody pair. Energy trans-
fer efficiencies below 5% were ignored as “background noise”.
Fig. 3, a and b show that there was substantial association
between CD45R0 and CD4 and CD8, respectively, but not
between CD45RBC or CD45RABC with CD4 or CD8. The en-
ergy transfer values for CD45R0-CD4/CD8 association were
found to be in the range 7.2–12.2%, demonstrating that a pool
of CD45R0 molecules are within 10 nm at the cell-surface of a
pool of CD4 or CD8 molecules. However, it should be noted that
these values do not provide information about the percentage of
molecules that associate. To confirm that these results were not
unique to a particular HPB-ALL sub-clone, the FRET analysis
for CD4-CD45R0 association was repeated on a total of five,
and the CD8-CD45R0 association repeated on three, independ-
ent CD45R0 sub-clones, with comparable results (data not
shown).
In light of recent reports that CD45 homodimerization may
regulate CD45 function, it was also of interest to determine
whether the various CD45 isomers homodimerized. To investi-
gate this question, FRET analysis using the FACS was carried
out on the different sub-clones labeled with a 50:50 mixture of
Cy3- and Cy5-CD45 F(ab) fragments. Fig. 3c shows that of the
three CD45 isoforms under investigation, only CD45R0 was
found as homodimers, generating energy transfer efficiency
values of 11.0  4.4 based on four independent experiments, in
contrast to 1.2  0.4 and 1.8  1.4 for the CD45RBC and
CD45RABC sub-clones, respectively.
The homodimerization of CD45R0, together with the prefer-
ential association of CD45R0 with CD4 and CD8 expressed on
the same cells, provided an interesting system for testing
whether CD45R0 might exert a dominantly positive effect on
signaling mediated by the TCR-CD4/CD8 complex, or whether
the possible inhibition of CD45 tyrosine phosphatase activity
by CD45R0 homodimerization might exert a negative effect on
TCR signaling. To distinguish these possibilities we carried out
a detailed investigation on the strength of TCR signal trans-
duction in the CD45RBC sub-clone compared with
CD45R0SD7, a sub-clone matched for p56
lck, CD3, CD45, CD4,
and CD8 expression (Fig. 2). We surmised that the close asso-
ciation between CD45R0 and CD4 molecules (Fig. 3a) might
generate a pool of CD4-associated p56lck that was more active
in the CD45R0 than in the CD45RBC sub-clone, due to
dephosphorylation of the inhibitory p56lck pTyr-505 by CD45.
To investigate this possibility, in vitro kinase assays were
carried out in CD4 immunocomplexes derived from cell-surface
CD4 molecules, and p56lck activity was assessed by autophos-
phorylation. Fig. 4a illustrates two representative experiments
demonstrating that the CD4-associated p56lck kinase activity
was, on average, 2-fold higher in the CD45R0 than in the
CD45RBC sub-clone. Consistent with this finding, basal pro-
tein tyrosine phosphorylation levels were consistently higher in
the CD45R0 than in the CD45RBC cells (Fig. 4b). Among the
hyper-phosphorylated proteins were the proto-oncogene c-Cbl
(38), p56lck, and the p21 TCR- phosphoisomer (arrowed in Fig.
4b; identification of the molecules is illustrated in Fig. 5). The
increased basal level of p21 TCR- phosphorylation is consist-
ent with the established role of p56lck in phosphorylating
TCR- (5, 6). The cell-surface expression of CD45R0 was rou-
tinely slightly higher than CD45RBC as revealed by FACS
staining using a pan-CD45 mAb (Fig. 2). When the CD45R0
cells were sorted to select a population with exactly the same
CD45 expression as the CD45RBC sub-clone, after a few days
in culture the CD45R0 expression became again slightly
FIG. 3. FRET analysis of CD45 isoform associations. HPB-ALL
sub-clones expressing CD45RABC, CD45RBC, or CD45R0 were labeled
with F(ab) fragments covalently bound to fluorescein (F) or rhodamine
(R) used as either donor or acceptor. Associations were estimated by
FACS analysis as described under “Experimental Procedures”. a and b
show the mean energy transfer efficiency values  S.D. calculated from
six independent experiments for CD4 and CD8 associations, respectively.
c, homodimerization analysis of CD45R0 (dashed line), CD45RABC (thick
solid line), and CD45RBC (thin solid line) by FACS analysis of cells
labeled with 50:50 mixtures of Cy-3/Cy-5-conjugated F(ab) fragments.
The data show are representative of four independent experiments.
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higher than the CD45RBC expression. To confirm that the
observed phosphorylation differences observed were not due to
subtle differences in CD45 expression, we therefore FACS-
sorted both the CD45R0 and CD45RBC sub-clones on the
same day to generate two populations with identical CD45
expression and then immediately repeated the phosphorylation
assays. Comparable differences were observed between the two
sub-clones as illustrated in Fig. 4b (data not shown). We there-
fore conclude that the small difference in expression of the two
isoforms was not the cause of the increased basal protein phos-
phorylation in the CD45R0 compared with CD45RBC
sub-clone.
Signaling assays were carried out to demonstrate that the
greater activity of the CD4-associated p56lck pool from
CD45R0 cells as measured in vitro was functionally more
effective in increasing the intensity of TCR signal transduction
coupling in vivo. We have previously shown that CD3-CD4
co-ligation greatly amplifies protein tyrosine phosphorylation
events in HPB-ALL cells in comparison with CD3-CD3 ligation
(31), presumably by enforced juxtaposition of CD4-p56lck with
its TCR polypeptide and ZAP-70 substrates. Immunoprecipita-
tion of the TCR- chain followed by immunoblotting for phos-
photyrosine showed that upon CD3-CD4 co-ligation, generation
of the TCR- p21 and p23 phosphoisomers was amplified in the
CD45R0 compared with the CD45RBC sub-clone (Fig. 5a).
Recruitment of ZAP-70 was also increased, as was tyrosine
phosphorylation of the kinase (Fig. 5a, upper panels). Consist-
ent with these results, CD3-CD4 co-ligation also increased the
tyrosine phosphorylation levels of multiple proteins to a
greater extent in CD45R0 compared with CD45RBC cells, as
shown by immunoblotting whole cell lysates for phosphoty-
rosine (Fig. 5b). This assay was also repeated for cells freshly
sorted for identical CD45 expression, as described above, with
comparable results (data not shown). Furthermore, amplified
CD3-CD4-induced protein tyrosine phosphorylation was also
observed in two other independent CD45R0 sub-clones
matched for cell-surface expression of CD3, CD4, CD8, and
CD45 (data not shown). A major phosphorylated protein that
migrated in the same position as p56lck, as shown by immuno-
blotting (Fig. 5b, middle panel), displayed both higher basal
and inducible tyrosine phosphorylation in CD45R0 than in
CD45RBC cells. Comparison of p56lck protein levels in the two
sub-clones, normalized by reference to Vav used as a loading
control (Fig. 5b, lower panel), confirmed that p56lck expression
levels were comparable. In contrast to CD3-CD4 co-ligation,
ligation of CD3 alone induced very little increase in protein
tyrosine phosphorylation in either the CD45R0 or CD45RBC
sub-clones (data not shown). However, as Fig. 5c illustrates, an
exception was the ability of CD3-stimulation to increase the
phosphorylation of a 120-kDa protein identified as c-Cbl (Fig.
5d). Whereas the increased Cbl phosphorylation was readily
detectable in CD45R0 cells, neither basal nor inducible phos-
phorylation of Cbl occurred in CD45RBC cells (Fig. 5c).
Identification of the major proteins tyrosine phosphorylated
upon CD3-CD4 co-ligation was carried out by immunoblotting
phosphotyrosine Fb2 mAb immunocomplexes and Grb-2 fusion
protein precipitates using specific antibodies. Fig. 5, d and e
identify the major 120-kDa protein illustrated in Fig. 5, b and
c as c-Cbl and confirms that Cbl phosphorylation was consid-
erably higher in the CD45R0 compared with the CD45RBC
sub-clone. Likewise ZAP-70 and p56lck proteins were both iden-
tified and confirmed using this approach as displaying in-
creased phosphorylation in the CD45R0 cells (Fig. 5d). Fur-
thermore, when the important signaling molecule Slp-76 was
precipitated using the Grb-2 fusion protein, inducible phospho-
rylation of the protein was greater in CD45R0 but not in
CD45RBC cells (Fig. 5e). An exception to this general pattern
was LAT, which had no detectable tyrosine phosphorylation
under basal conditions in either sub-clone, but showed compa-
rable phosphorylation levels following CD3-CD4 co-ligation in
both sub-clones (Fig. 5d). Further investigation, however,
showed that this anomaly was readily explained by the much
reduced expression of LAT protein in the CD45R0 compared
with the CD45RBC sub-clone (Fig. 5d, lowest panel), whereas
Cbl (Fig. 5d), p56lck (Fig. 5b), and ZAP-70 (Fig. 1 and data not
shown) expression levels were all comparable.
Overall these results show that the intensity of TCR signal
transduction coupling was much greater when CD45R0
rather than CD45RBC was expressed at the cell-surface.
DISCUSSION
The most important finding presented in this paper is that
CD45R0, but not the CD45RBC or CD45RABC isoforms, forms
heterodimers with CD4 and CD8 at the cell-surface of HPB-
ALL T cells and also exists as CD45R0 homodimers (Fig. 3),
associations that correlate with elevated basal kinase activity
of CD4-associated p56lck (Fig. 4) and increased intensity of TCR
signaling phosphorylation events (Fig. 5). These findings rep-
resent the first report that CD45R0 preferentially forms ho-
modimers and the first time that CD4/CD8-CD45R0 associa-
tions have been described using non-invasive FRET
technology, obviating the need for antibody-induced co-capping
or for exposing cells to detergent. A concern in co-capping
studies is that the molecular composition of the cap, normally
examined after prolonged periods (10–30 min) of antigen cross-
linking (23, 24), might not reflect basal-state associations be-
tween the same molecules. Furthermore, a very large range of
cell-surface molecules have been reported to associate with
CD45 following co-immunoprecipitation from detergent cell ly-
sates (reviewed in Ref. 1); CD45 is an abundant and heavily
FIG. 4. CD4-associated p56lck kinase activity and protein phos-
phorylation under basal conditions. a, p56lck kinase autophospho-
rylation assays were carried out in CD4 immunocomplexes. The results
illustrate two representative experiments, and the values shown are
the ratios of p56lck kinase values between CD45R0 and CD45RBC
HPB-ALL sub-clones. b, whole cell lysates were immunoblotted for
phosphotyrosine (upper panel) and for the 16-kDa TCR- chain as a
loading control (lower panel).
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glycosylated molecule, and the possibility that nonspecific as-
sociations may occur during the immunoprecipitation process
becomes correspondingly high. Nevertheless, our findings
based on FRET are consistent with the previously described
co-capping of CD4 with CD45R0 (23) and the co-immunopre-
cipitation of CD4 and CD45 from detergent lysates of primary
resting CD4 T cells (26), although not with the reported
preferential association between CD45R0 and the TCR (24).
Interestingly, an earlier study also using FRET analysis re-
ported that association of CD45 with CD4 and CD8 only oc-
curred following 72–96 h of TCR stimulation (25). Although
specific CD45 isoforms were not characterized in this investi-
gation, it is known that CD45R0 expression markedly in-
creases on activated T cells (39), and it therefore seems very
likely that the observed CD4/CD8-CD45 associations detected
involved the CD45R0 isoform. A further possibly relevant ob-
servation is that whereas CD4 was found clustered with TCR-
at the central initiating locus of the immune synapse (the
“c-SMAC”), within a few minutes the CD4 moved to a more
peripheral location (40). It will be interesting to determine
whether the relatively small CD45R0 isoform may be localized
in the c-SMAC with CD4 prior to re-localization into a less
central position. It is possible that the reported exclusion of
CD45 from the immune synapse (41) might selectively apply to
CD45 isoforms encoding A/B/C exon products rather than to
CD45R0.
The mechanism of CD45R0 association with CD4 and CD8
remains unknown. The association could be mediated by an
intermediary molecule such as the transmembrane leukocyte
phosphatase-associated molecule (LPAP) (42), but it is not ap-
parent how leukocyte phosphatase-associated molecule might
mediate the selectivity of the interactions and LPAP/ mice do
not display an obvious phenotype (43). More likely are direct
interactions between binding motifs in the respective polypep-
tide back-bones and/or oligosaccharide interactions. The CD45
A, B, and C exon products contribute much of the heavy glyco-
sylation that characterizes CD45, and the absence of this re-
gion causes a large reduction in the size of the CD45 ectodo-
main (44). It is possible that CD45-CD4/CD8 binding
represents the “default” association state and that this is pre-
vented by the A-C exon products. Similarly CD45R0 homoas-
sociation might represent the default position of CD45 mole-
cules that is also prevented, for example, by the heavy
sialylation associated with the A-C exon region. We are cur-
FIG. 5. CD3-CD4 and CD3-CD3 stimulated phosphorylation events in CD45R0 compared with CD45RBC HPB-ALL sub-clones. a,
cells were stimulated by CD3-CD4 co-ligation for the times shown before immunoprecipitating TCR- and blotting for phosphotyrosine; the blot was
then stripped and re-probed for ZAP-70 and TCR-. b, cells were stimulated by CD3-CD4 co-ligation before immunoblotting whole cell lysates for
phosphotyrosine (upper panel), p56lck (middle panel), or for Vav (lower panel) as a loading control. c, cells were stimulated using a cross-linked CD3
mAb for the times shown, and whole cell lysates immunoblotted for phosphotyrosine (upper panel) and for tubulin (lower panel) as a loading control.
The phosphorylated band was identified as c-Cbl as shown in d and e. d, cells were stimulated by CD3-CD4 co-ligation, and tyrosine phosphorylated
proteins were then immunoprecipitated using the Fb2 phosphotyrosine mAb followed by immunoblotting for c-Cbl, ZAP-70, p56lck, and LAT as
indicated (upper panel). The lower panel shows immunoblotting of whole cell lysates for LAT using c-Cbl as a loading control. e, cells were
stimulated by CD3-CD4 co-ligation followed by precipitation of proteins bound to a Grb-2 fusion protein. Precipitates were blotted for phospho-
tyrosine, and the blot was then stripped and re-probed for c-Cbl and Slp-76.
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rently investigating the mechanisms involved in the associa-
tions revealed by FRET analysis.
The finding that CD45R0 homodimers, as well as CD4-
CD45R0 and CD8-CD45R0 heterodimers, were present at the
cell-surface of HPB-ALL cells (Fig. 3) raises the question as to
whether CD4 and/or CD8 are in competition with CD45R0 to
decrease the extent of CD45R0 homodimerization. The expres-
sion of both CD4 and CD8 is high in these cells (Fig. 2), but
whether homodimerization might increase as CD4/CD8 expres-
sion levels are decreased is not yet known. It also remains
formally possible that the CD45R0 that associates with CD4
and/or CD8 is homodimeric, a possibility currently under in-
vestigation. Our findings do not exclude the possibility that
CD45R0 homodimerization inhibits the CD45 PTPase activity
(29), but the dominant effect of CD45R0 in the present exper-
imental context was to associate with CD4/CD8 (Fig. 3) and to
amplify TCR signal transduction coupling by generating a
more active pool of CD4-associated p56lck kinase molecules
(Fig. 4a). Nevertheless it remains possible that the increased
TCR signaling intensity observed may be explained by second-
ary changes in other “third party” signaling molecules regu-
lated by differential CD45 isoform expression. The downstream
consequences of increased intensity of TCR signal transduction
coupling are expected to reflect the balance between concomi-
tant amplification of both positive and negative signals. For
example, c-Cbl, a major tyrosine kinase substrate in HPB-ALL
cells (Fig. 5), is well established as a negative regulator of
immune receptor signal transduction (38), and its coupling to
downstream effectors appears to be tyrosine phosphorylation-
dependent (45, 46). A comparison of downstream signaling
pathways in HPB-ALL cells expressing different isoforms will
be described in a separate paper.
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